Renewed rationale for sex- and gender-disaggregated research: A COVID-19 commentary review

Kelly Thompson1*, Amy Vassallo1*, Simon Finfer1,2*, and Mark Woodward1,2

Abstract

The COVID-19 pandemic provides a contemporaneous illustration of the need to consider sex and gender in research. Using surveillance, treatment and vaccine research examples, in this commentary review, we highlight opportunities for innovation in sex- and gender-sensitive and transformative health and medical research.

Keywords

COVID-19, gender, gender differences, infectious diseases, sex, sex differences

Date received: 24 August 2021; revised: 5 January 2022; accepted: 11 January 2022

Introduction

Sex- and gender-disaggregated analysis is critical to the interpretation, validation, reproducibility and generalizability of research findings.1 Reports of the epidemiology of the SARS-CoV-2 pandemic and treatment effects in clinical trials for the resultant clinical disease, COVID-19, provide a contemporaneous illustration of how sex and gender impact health.2 For example, global data indicate men to be more likely to acquire more severe forms of COVID-19 and die from it.2 Incorporating sex-disaggregated analysis is important when women and men may be more (or less) likely to acquire severe forms of disease and where treatment effects depend on disease severity.3

In this commentary review, we report evidence gaps and opportunities for discovery through the collection, analysis and reporting of sex- and gender-sensitive COVID-19 surveillance, prevention and treatment data. We provide practical recommendations for collecting and reporting data, including the importance of moving beyond the gender binary, and discuss how different research stakeholders can improve research integrity through the mandatory incorporation of sex- and gender-disaggregated analyses.

As this study is a commentary review, informed consent was not sought nor relevant. The purpose of a commentary review is to provoke scholarly dialogue.4 Research methodology is not typically presented, and the selection and synthesis of included articles demonstrates author bias.4 The authors have combined expertise in sex-disaggregated data analysis, women’s health and critical care/sepsis research. Having closely followed evidence generated from the pandemic, we have selected examples to broadly demonstrate why the consideration of sex and gender in health and medical research is important.

Surveillance data

Binary sex-disaggregated data show essentially equal numbers of confirmed COVID-19 cases in females (49%) and males (51%). Although women are more likely to be tested, men are more likely to acquire a severe COVID-19-related illness, and account for a higher proportion of
hospitalisations (53%), intensive care unit admissions (64%) and deaths (57%). Only half of all countries report COVID-19 cases and deaths by (male or female) sex, and only 28 (14%) and 19 (9.5%) countries report sex-specific hospitalization and intensive care unit (ICU) admission data, respectively. By July 2021, several countries that had previously reported sex-disaggregated COVID-19 cases and deaths were no longer reporting these data to Global Health 50/50. This is despite the World Health Organization (WHO) Strategy for integrating gender analysis and actions into the work of WHO, which encourages Member States to improve the collection, analysis and use of quantitative data on health, disaggregated by sex, age and other relevant social stratifications.

Although sex segregation of data overlooks other intersecting social and demographic variables which influence health, including age, ethnicity and gender norms, these data are needed to understand the impacts of COVID-19 in the community and highlight areas for further investigation and targeted intervention. Only through standard collection and reporting of sex-disaggregated surveillance data can future analysis of COVID-19 outcomes by sex, age, ethnicity and the interactions between these factors be possible. This includes investigations to understand gender-related influences, such as how gender norms influence exposure and access to testing and treatment.

Clinical trials

The impoverished state of sex-sensitive or specific COVID-19 clinical research has been previously reported. In a scoping review of 30 pharmacological prevention and treatment trials, one study included a post hoc sex-specific analysis. Sex-stratified randomization or assessment of treatment effects by sex is absent from preliminary reports of evidence that have led to practice changes globally. Between December 2020 and January 2021, 13.8 million vaccine doses were administered in the United States, with 61% administered to females. The Centre for Disease Control reported 79.1% of reported adverse events with 61% administered to females. The Centres for Disease Control reported 79.1% of reported adverse events with 61% administered to females. The Centres for Disease Control reported 79.1% of reported adverse events with 61% administered to females.

For example, in the RECOVERY trial of corticosteroids (dexamethasone), compared to usual care, in hospitalized COVID-19 patients, the investigators observed an 18% reduction in 28-day risk of death for patients receiving dexamethasone and requiring oxygen therapy. The treatment was most effective in mechanically ventilated patients where the risk of death reduced by 36%. The preliminary results of the trial were adopted into UK practice on the day of publication. Although females accounted for one-third of the study population, and were less likely than males to be mechanically ventilated, the authors did not report treatment effects by sex. In a post hoc analysis of a similar trial of corticosteroids in mechanically ventilated patients with septic shock, females who received corticosteroid had a significant risk of shock recurrence, compared to males. Although the evidence of a sex difference in response to corticosteroid for patients with severe infection is weak, whether corticosteroids reduce mortality in patients with septic shock has been studied by intensive care researchers for over half a century. Of 22 published trials including 7297 patients, there has been one post hoc analysis of treatment effects by sex.

Addressing the pitfalls of underpowered and insufficiently informative studies as research pivots to describe and address the long-term sequelae of SARS-CoV-2 infection is key. Long COVID, which occurs in more than one-third of survivors who report at least one symptom for 12 weeks or more, with women at an increased risk, compared to men (odds ratio (OR) = 1.51; 95% confidence interval (CI) = 1.46–1.55) represents an important opportunity for discovery and innovation. As recruitment for Long COVID trials, like HEAL-COVID – a platform trial based on the RECOVERY model, commences, trialists should take stock of the evidence of sex and gender differences in COVID-19 and incorporate sex-stratified randomization or, at the very least, incorporate an assessment of treatment effects by sex. This consideration may prove to be of great benefit not only to patients and society but also to science.

Vaccine safety

Vaccine studies have frequently demonstrated that females tend to develop stronger innate and adaptive immune responses to vaccines compared to males. Subsequently, vaccine-related side effects and adverse events are more common in females, having been widely reported for influenza, yellow fever, measles, mumps, rubella, hepatitis A and B, herpes simplex 2, rabies, dengue and smallpox vaccines. Very few trials of COVID-19 vaccines currently in use have reported the influence of sex on safety and efficacy outcomes.

Between December 2020 and January 2021, 13.8 million vaccine doses were administered in the United States, with 61% administered to females. The Centre for Disease Control reported 79.1% of reported adverse events occurred in females. Incorporating sex-specific analyses in COVID-19 vaccine trials would have enabled a comprehensive understanding of sex differences in immune response and the opportunity to develop, test and implement sex-specific strategies to mitigate the surplus of adverse side effects experienced by women. While the opportunity to understand and improve sex-specific vaccine impacts has been missed, gender-related factors associated with equitable vaccine access, including vaccine hesitancy, remain an important consideration.

Moving beyond binary sex and gender

Epidemiological and clinical research surrounding the COVID-19 pandemic has primarily used binary terms for sex and gender (male/man/men and female/woman/women). There are a variety of ways sex and/or gender data are collected for clinical research, including population registries, healthcare records or survey self-report. However,
binary terms, particularly sex assigned at birth, are inaccurate for people who are transgender, non-binary or have variations of sex characteristics, also known as intersex. To enable a nuanced understanding of what is required for safe and effective care of all genders, a multistep approach is being increasingly recommended to accurately collect information about biological sex and gender identity.\(^1\)

**What can research stakeholders do?**

In the past two decades, improvements in understanding of sex and gender influences in health and disease has led to major granting agencies, including the Canadian Institutes of Health Research, the US National Institutes of Health and the EU Commission, requiring an explanation of how sex and gender analysis is relevant to, and incorporated into, grant proposals.\(^2\) Several peer-reviewed journals have adopted the Sex and Gender Equity in Research (SAGER) guidelines,\(^3\) although the degree to which their authors follow them is not always clear.\(^9\)

To facilitate health equity for all genders, future pandemic preparedness and response planning should include sex- and gender-responsive research, including routine inclusion of sex- and/or gender-specific analyses in epidemiology studies, clinical trials and implementation research. To support this, evidence-informed actionable steps to researchers, peer-reviewed journals and research funders are provided in Table 1.

### Conclusion

The COVID-19 pandemic has demonstrated sex and gender differences in disease epidemiology, prevention, treatment and outcomes, advancing the evidence for the mandatory inclusion of sex- and gender-disaggregated analysis in health and medical research. This research is critical to the validation, interpretation, reproducibility and generalizability of research findings and a responsibility of all stakeholders in the global research community.

**Author contribution(s)**

**Kelly Thompson:** Conceptualization; investigation; methodology; project administration; writing – original draft; writing – review and editing.  
**Amy Vassallo:** Data curation; writing – original draft; writing – review and editing.  
**Simon Finfer:** Writing – review and editing.  
**Mark Woodward:** Supervision; writing – review and editing.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship and/or publication of this article.

**ORCID iDs**

Kelly Thompson [ID](https://orcid.org/0000-0003-2304-8931)  
Simon Finfer [ID](https://orcid.org/0000-0002-2785-5864)

**References**

1. Accounting for sex and gender makes for better science. *Nature* 2020; 588(7837): 196.  
2. Global Health 50:50. The COVID-19 sex disaggregated data tracker. May update report, 2021, [https://globalhealth5050.org/wp-content/uploads/May-2021-Data-Tracker-Update.pdf](https://globalhealth5050.org/wp-content/uploads/May-2021-Data-Tracker-Update.pdf)  
3. Thompson K, Venkatesh B, Hammond N, et al. Sex differences in response to adjunctive corticosteroid treatment for patients with septic shock. *Intensive Care Med* 2021; 47(2): 246–248.  
4. Green BN, Johnson CD and Adams A. Writing narrative literature reviews for peer-reviewed journals: secrets of the trade. *J Chiropr Med* 2006; 5(3): 101–117.  
5. Liu B, Spokes P, He W, et al. High risk groups for severe COVID-19 in a whole of population cohort in Australia. *BMC Infect Dis* 2021; 21(1): 685.
6. World Health Organization. Strategy for integrating gender analysis and actions into the work of WHO, 2009, https://www.who.int/publications/i/item/WHO-FCH-GWH-08.1
7. Heidari S, Ahumada C, Kurbanova Z, et al. Towards the real-time inclusion of sex- and age-disaggregated data in pandemic responses. *BMJ Glob Health* 2020; 5(10): e003848.
8. Rushovich T, Boulcault M, Chen JT, et al. Sex Disparities in COVID-19 mortality vary across US racial groups. *J Gen Intern Med* 2021; 36(6): 1696–1701.
9. Palmer-Ross A, Ovseiko PV and Heidari S. Inadequate reporting of COVID-19 clinical studies: a renewed rationale for the Sex and Gender Equity in Research (SAGER) guidelines. *BMJ Glob Health* 2021; 6(4): e004997.
10. Schiffer VM, Janssen EB, van Bussel BC, et al. The ‘sex gap’ in COVID-19 trials: a scoping review. *Eclinicalmedicine* 2020; 29: 100652.
11. Dexamethasone in hospitalized patients with Covid-19. *N Engl J Med* 2020; 384(8): 693–704.
12. Rygård SL, Butler E, Granholm A, et al. Low-dose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis. *Intensive Care Med* 2018; 44: 1003–1016.
13. Bugin K and Woodcock J. Trends in COVID-19 therapeutic clinical trials. *Nat Rev Drug Discov* 2021; 20(4): 254–255.
14. Whitaker MEJ, Chadeau-Hyam M, Riley S, et al. Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people. London: Institute of Global Health Innovation, Imperial College London, 2021.
15. Mullard A. Long COVID’s long R&D agenda. *Nat Rev Drug Discov* 2021; 20(5): 329–331.
16. Flanagan KL, Fink AL, Plebanski M, et al. Sex and gender differences in the outcomes of vaccination over the life course. *Annu Rev Cell Dev Biol* 2017; 33: 577–599.
17. Klein SL, Jedlicka A and Pekosz A. The Xs and Y of immune responses to viral vaccines. *Lancet Infect Dis* 2010; 10(5): 338–349.
18. Centers for Disease Control Prevention. First Month of COVID-19 vaccine safety monitoring – United States, December 14 2020–January 13 2021. Morbidity and Mortality Weekly Report (MMWR) 2021, https://www.cdc.gov/mmwr/volumes/70/wr/mm7008e3.htm
19. Alpert AB, Ruddick R and Manzano C. Rethinking sex-assigned-at-birth questions. *BMJ* 2021; 373: n1261.
20. Tannenbaum C, Ellis RP, Eyssel F, et al. Sex and gender analysis improves science and engineering. *Nature* 2019; 575(7781): 137–146.
21. Heidari S, Babor TF, De Castro P, et al. Sex and gender equity in research: rationale for the SAGER guidelines and recommended use. *Res Integr Peer Rev* 2016; 1(1): 2.
22. Nielsen MW, Andersen JP, Schiebinger L, et al. One and a half million medical papers reveal a link between author gender and attention to gender and sex analysis. *Nat Hum Behav* 2017; 1(11): 791–796.
23. Tadiri CP, Raparelli V, Abramowicz M, et al. Methods for prospectively incorporating gender into health sciences research. *J Clin Epidemiol* 2021; 129: 191–197.